Clinical Edge Journal Scan

Lower serum bile acid levels independently predict adverse renal outcomes in T2DM and DKD


 

Key clinical point: Lower serum bile acid levels (≤2.8 mmol/L) were an independent predictor of progression of diabetic kidney disease (DKD) to end-stage renal disease (ESRD) in patients with type 2 diabetes mellitus (T2DM) and biopsy-proven DKD.

Major finding: Overall, 34.78% of patients progressed to ESRD during a median follow-up of 19.02 months, with lower levels of serum bile acids being independently associated with a higher risk for progression to ESRD (adjusted hazard ratio, 5.319; P = .027).

Study details: This was a retrospective cohort study including 184 patients with T2DM and biopsy-proven DKD.

Disclosures: This study was supported by the Health Commission of Sichuan Province Program. The authors declared no conflict of interests.

Source: Xiao X et al. Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease. Front Endocrinol (Lausanne). 2022;13:1026995 (Oct 7). Doi: 10.3389/fendo.2022.1026995.

Recommended Reading

Yoga and other mind-body work good for diabetes control
Type 2 Diabetes ICYMI
Tirzepatide vs. insulin glargine improves renal outcomes in T2D
Type 2 Diabetes ICYMI
Antidiabetic drugs influence fracture risk in T2D
Type 2 Diabetes ICYMI
T2D: Increased risk for ventricular arrhythmia or sudden cardiac death with sulfonylurea vs metformin
Type 2 Diabetes ICYMI
T2D: Bexagliflozin add-on to metformin shows antidiabetic potency equivalent to glimepiride
Type 2 Diabetes ICYMI
Saxagliptin add-on to oral antihyperglycemic agents safe and effective in drug-naive T2D patients
Type 2 Diabetes ICYMI
Metformin may offer more neuroprotection for dementia than sulfonylurea in T2D
Type 2 Diabetes ICYMI
Metformin ups gastrointestinal adverse event risk in T2D
Type 2 Diabetes ICYMI
Adding antihypertensive to standard diabetes therapy improves glycemic control in T2DM
Type 2 Diabetes ICYMI
No increase in risk for major adverse limb events with SGLT-2i vs. GLP-1RA in T2DM
Type 2 Diabetes ICYMI